Advaxis’ Cervical Cancer Treatment Trial Shows Progress in Survival Rate Print E-mail
By FDAnews Drug Daily Bulletin   
Saturday, 26 September 2015 00:57

A trial of a cervical cancer treatment by New Jersey biotech company Advaxis demonstrated it could extend life further than existing treatments in women with persistent, advanced forms of the disease.

 

Among the high-risk patients placed on the immunotherapy therapy axalimogene filolisbac and studied through a one-year period, there was a 38.5 percent survival rate, the company said last week.

   

Conducted by the nonprofit Gynecologic Oncology Group, the first-stage of the Phase 2 trial monitored how three doses administered over three months influenced the health of 26 patients who had not improved with other treatment options.

    

Many of the women (73 percent) experienced low-grade safety concerns — mostly fatigue, chills and fever. Four patients had more serious health risks, including hypotension and cytokine release syndrome, and one fell ill with a lung infection and sepsis. 

    

READ MORE AT FDANews.com




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter